The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing
Abstract
DNA repair, one of the fundamental processes occurring in a cell, safeguards the genome and maintains its integrity. Among various DNA lesions, double‐strand breaks are considered to be the most deleterious, as they can lead to potential loss of genetic information, if not repaired. Nonhomologous end joining (NHEJ) and homologous recombination are two major double‐strand break repair pathways. SCR 7, a DNA ligase IV inhibitor, was recently identified and characterized as a potential anticancer compound. Interestingly, SCR 7 was shown to have several applications, owing to its unique property as an NHEJ inhibitor. Here, we focus on three main areas of research in which SCR 7 is actively being used, and discuss one of the applications, i.e. genome editing via CRISPR/Cas, in detail. In the past year, different studies have shown that SCR 7 significantly increases the efficiency of precise genome editing by inhibiting NHEJ, and favouring the error‐free homologous recombination pathway, both in vitro and in vivo. Overall, we discuss the current applications of SCR 7 to shed light on the unique property of the small molecule of having distinct applications in normal and cancer cells, when used at different cellular concentrations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One of the most commonly used inhibitors, Scr7, targets the NHEJ component DNA ligase IV, and has been reported to increase efficiency of HDR from Cas9 editing by up to 19-fold (Srivastava et al., 2012; Chu et al., 2015; Vartak & Raghavan, 2015).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Vartak & Raghavan, 2015
Citations
Cites
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Small molecules enhance CRISPR genome editing in pluripotent stem cells
Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.003 · Cited by 455
Research works printed but not linked: 23
- 10.1146/annurev-genet-110711-155540 · DOI · Paper page
- 10.1016/j.chembiol.2014.11.013 · DOI · Paper page
- 10.1016/j.dnarep.2006.05.026 · DOI · Paper page
- 10.1146/annurev.genet.40.110405.090451 · DOI · Paper page
- 10.1038/nrc3537 · DOI · Paper page
- 10.1126/science.1261971 · DOI · Paper page
- Davis AJ, 2013, DNA double strand break repair via non‐homologous end‐joining, Transl Cancer Res, 2, 130
- 10.1038/sj.onc.1204148 · doi:10.1038/sj.onc.1204148
- 10.1111/j.1349-7006.2003.tb01372.x · DOI
- 10.1016/j.cell.2012.11.054 · DOI · Paper page
- 10.1039/C4FD00176A · DOI
- 10.1002/mabi.201400480 · DOI
- 10.1073/pnas.1420115112 · DOI · Paper page
- 10.1016/j.cell.2014.05.010 · DOI · Paper page
- 10.1038/nrmicro1793 · DOI · Paper page
- 10.1038/nrmicro3241 · DOI · Paper page
- 10.1038/nchembio.1793 · DOI · Paper page
- 10.1534/g3.112.005439 · DOI
- 10.1101/gad.946401 · DOI · Paper page
- 10.1016/j.jmb.2012.01.029 · DOI
- 10.1007/s00438-005-1112-2 · DOI
- 10.1038/nbt.3198 · DOI · Paper page
- 10.1534/genetics.114.169771 · DOI · Paper page
Cited by
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Methodologies for Improving HDR Efficiency
Liu, M., Rehman, S., Tang, X., Gu, K., Fan, Q., Chen, D., & Ma, W. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00691 · Cited by 323
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 283
Metadata
- Authors
- Vartak, S. V., & Raghavan, S. C.
- Affiliations
- Department of Biochemistry Indian Institute of Science Bangalore India
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2015-09-09
- Volume
- 282
- Issue
- 22
- Pages
- 4289-4294
- ISSN
- 1742-464X
- 1742-4658
- Cited by
- 92
- References
- 4
- Language
- en
- Funders
- IISc-DBT partnership programme (DBT/BF/PR/INS/2011-12/IISc)
- IISc, Bangalore, India
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing. https://app.cochat.ai/papers/10.1111/febs.13416
- The paper
- Vartak, S. V., & Raghavan, S. C. (2015). Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing. The FEBS Journal. https://doi.org/10.1111/febs.13416
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.